BOTHELL, Wash.--(BUSINESS WIRE)--BTG plc (LSE: BTG), the global healthcare company, highlighted the presentation of the two-year results for the SENTRY trial, at the Vascular Interventional Advances ...

BOTHELL, Wash.--(BUSINESS WIRE)--BTG plc (LSE: BTG), the global healthcare company, today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. LAS VEGAS — Use of a bioconvertible inferior vena cava ...

LAS VEGAS — Use of a bioconvertible inferior vena cava filter successfully prevented new-onset pulmonary embolism in high-risk patients and was bioresorbed within 1 year in most cases, according to ...

The Inferior Vena Cava (IVC) filter is a crucial medical device designed to prevent the occurrence of a pulmonary embolism (PE), a condition that can be fatal if untreated. The Inferior Vena Cava (IVC ...

LAS VEGAS, NV—Several novel bioresorbable devices were presented here this week at VIVA 2018 in late-breaking trial sessions. One offered a unique way to close large femoral artery access sites ...

BTG, a British specialist healthcare group has acquired Novate Medical, a pulmonary embolism-focused medtech startup. While the upfront fee is a modest $20 million, BTG is on the hook for up to $130 ...

in reducing potential complications seen with conventional filters.